查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1494900

到 2030 年疫苗佐劑市場預測：按佐劑類型、疾病類型、疫苗類型、給藥途徑、應用、最終用戶和地區進行的全球分析

Vaccine Adjuvants Market Forecasts to 2030 - Global Analysis By Adjuvant Type (Alum, Liposomes, Viral-Derived Particles and Other Adjuvants Types), Disease Type, Vaccine Type, Route of Administration, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據Stratistics MRC預測，2024年全球疫苗佐劑市場規模將達8億美元，預計2030年將達到14億美元，預測期內年複合成長率為8.9%。

疫苗佐劑是一種添加到疫苗中以增強對疫苗抗原的免疫反應的物質。佐劑有助於產生更強、更持久的免疫反應，減少抗原的量和免疫所需的劑量數量。佐劑包括活化免疫系統的活化和更有效地將抗原呈現給免疫細胞的遞送系統。

根據世界衛生組織（WHO）報告，全球人類疫苗市場從2000年的60億美元成長到2014年的330億美元和2018年的364.5億美元，其中高所得國家的銷售額約佔65%的總銷售額。

感染疾病增加

隨著全球感染疾病負擔持續增加，越來越需要有效的疫苗來預防和控制這些疾病。佐劑在提高疫苗的免疫抗原性和功效方面發揮重要作用，使疫苗更有效、更持久。流感、瘧疾、結核病等感染疾病以及 COVID-19 等新出現的病原體的高流行進一步加速了對佐劑疫苗的需求。因此，感染疾病的傳播增加了對疫苗佐劑的需求，推動市場成長。

開發和製造成本高

疫苗佐劑的高開發和製造成本是市場的主要限制因素。開發過程複雜且耗時，需要在研發、生產設施和專業知識方面進行大量投資。疫苗開發可能需要數年時間並且成本高昂。高故障率挑戰製造商獲得資金並支付營運成本。

新疫苗的開發

隨著研究人員致力於開發針對愛滋病毒、瘧疾和癌症等挑戰性疾病的疫苗，越來越需要強大的佐劑來提高這些疫苗的有效性。新型佐劑可刺激更強、更有針對性的免疫反應，減少所需抗原的量，並使新的疫苗遞送方法的使用成為可能。對皂素、TLR促效劑、奈米粒子和黏膜佐劑等佐劑的持續研究預計將導致更有效和創新的疫苗的開發。對新疫苗和改進疫苗的需求不斷成長預計將推動未來幾年疫苗佐劑市場的成長。

嚴格的監管要求

嚴格的監管要求對市場構成重大威脅，因為新助劑的核准過程既耗時又昂貴。要滿足 FDA 和 EMA 等監管機構制定的嚴格安全性和有效性標準，需要大量的臨床前和臨床資料，從而延長產品開發時間。此外，監管障礙和核准延遲可能會阻礙市場進入並限制創新。遵守複雜的法律規範會為企業帶來經濟負擔和不確定性，影響競爭力和市場成長。

COVID-19 的影響：

COVID-19大流行對疫苗佐劑市場產生了積極影響。隨著研究人員探索不同的配方來增強對病毒的免疫反應，對有效疫苗的迫切需求推動了佐劑技術的進步。因此，疫情期間佐劑的需求增加，且這一趨勢預計將持續下去。這場危機加速了佐劑的創新和發現，對未來的疫苗開發有廣泛的影響。

在預測期內，感染疾病領域預計將是最大的。

由於全球感染疾病發病率不斷上升以及對有效疫苗的迫切需求，預計感染疾病領域將在預測期內主導疫苗佐劑市場。這一成長是由政府對免疫計劃的承諾和資金的增加以及提高疫苗功效的佐劑技術的進步所推動的。此外，感染疾病預防意識的提高以及針對新出現病原體的疫苗開發的進展也有助於該領域的主導地位。

預計肌肉注射領域在預測期內年複合成長率最高。

預計在預測期內，肌肉注射細分市場將成為疫苗佐劑市場中年複合成長率最高的領域。這是因為肌肉注射是最常見的疫苗接種方法，可以有效地將疫苗輸送到血液供應豐富且含有對疫苗快速反應的免疫細胞的肌肉組織。與皮下或皮內給藥相比，肌肉給藥也降低了局部反應的風險。此外，強烈建議將許多含有佐劑的疫苗進行肌肉注射，以最佳化免疫抗原性並最大限度地減少副作用。

佔比最大的地區：

由於亞太地區人口眾多、感染疾病流行率不斷上升以及人們對疫苗接種益處的認知不斷增強，預計亞太地區將佔據疫苗佐劑市場的最高市場佔有率。此外，政府措施、對醫療基礎設施的投資、主要市場參與者的存在以及不斷擴大的生物製藥產業都有助於市場成長。除了該地區對創新研發的重視外，有利的法規環境也進一步拉動了亞太地區對疫苗佐劑的需求。

年複合成長率最高的地區：

由於先進的醫療基礎設施、積極的研發活動以及對疫苗開發的高投資，預計北美在預測期內將在疫苗佐劑市場中表現出最高的年複合成長率。該地區受益於政府的大力支持、有利的法規結構以及感染疾病的高流行，推動了對有效疫苗的需求。此外，大型生物製藥公司的存在以及人們對疫苗接種重要性的認知不斷提高也促進了北美市場的快速成長。

免費客製化服務

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與者的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計、預測和年複合成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 研究資訊來源
    • 主要研究資訊來源
    • 二次研究資訊來源
    • 先決條件

第3章市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 應用分析
  • 最終用戶分析
  • 新興市場
  • COVID-19 的影響

第4章波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章全球疫苗佐劑市場：按佐劑類型

  • 明礬（氫氧化鋁）
  • 脂質體
  • 病毒衍生顆粒 (VDP)
  • 乳液
  • 碳水化合物佐劑
  • 張力活性佐劑
  • 有機佐劑
  • 礦物鹽類佐劑
  • 其他佐劑類型

第6章全球疫苗佐劑市場：依疾病類型

  • 感染疾病
  • 癌症
  • 其他疾病類型

第7章全球疫苗佐劑市場：依疫苗類型

  • 病毒疫苗
  • 細菌疫苗
  • 寄生蟲疫苗
  • 其他疫苗類型

第8章全球疫苗佐劑市場：依給藥途徑

  • 肌肉注射
  • 皮下的
  • 鼻腔
  • 口服
  • 皮內

第9章全球疫苗佐劑市場：依應用分類

  • 研究用途
  • 商業用途

第10章全球疫苗佐劑市場：依最終用戶分類

  • 人類疫苗佐劑
  • 獸用疫苗佐劑

第11章全球疫苗佐劑市場：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東/非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲

第12章 主要進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第13章 公司概況

  • GlaxoSmithKline plc（GSK）
  • CSL Limited
  • Novavax, Inc.
  • SPI Pharma, Inc.
  • Seppic（Air Liquide）
  • Invivogen
  • Croda International Plc
  • Dynavax Technologies Corporation
  • Adjuvance Technologies Inc.
  • Agenus Inc.
  • OZ Biosciences
  • Avanti Polar Lipids, Inc.
  • MVP Laboratories, Inc.
  • Vaxine Pty Ltd
  • GlycoMira Therapeutics Inc.
  • Pfizer Inc.
  • Sanofi
  • Merck & Co., Inc.
  • Zoetis Inc.
  • Moderna, Inc.
Product Code: SMRC26420

According to Stratistics MRC, the Global Vaccine Adjuvants Market is accounted for $0.8 billion in 2024 and is expected to reach $1.4 billion by 2030 growing at a CAGR of 8.9% during the forecast period. Vaccine adjuvants are substances added to vaccines to enhance the immune response to the vaccine antigen. They help create a stronger and longer-lasting immune response, reducing the amount of antigen needed and the number of doses required for immunity. Adjuvants can be immunostimulants that activate the immune system or delivery systems that present the antigen more effectively to immune cells.

According to a report by the World Health Organization (WHO), the global human vaccine market grew from USD 6 billion in 2000 to USD 33 billion in 2014 and USD 36.45 billion in 2018, with sales to high-income countries representing about 65% of the total value.

Market Dynamics:

Driver:

Rising prevalence of infectious diseases

As the global burden of infectious diseases continues to grow, there is an increasing demand for effective vaccines to prevent and control these diseases. Adjuvants play a crucial role in enhancing the immunogenicity and efficacy of vaccines, making them more potent and long-lasting. The high incidence rates of infectious diseases such as influenza, malaria, tuberculosis, and emerging pathogens like COVID-19 have further accelerated the need for adjuvanted vaccines. Consequently, the growing prevalence of infectious diseases is propelling the demand for vaccine adjuvants and driving market growth.

Restraint:

High cost of development and manufacturing

The high cost of developing and manufacturing vaccine adjuvants is a significant restraint in the market. The development process is complex, time-consuming, and requires substantial investment in research and development, production facilities, and specialized knowledge. Vaccine development can take a few years, and it comes at a high cost. The high failure rate makes it challenging for manufacturers to secure funds and cover operational expenses.

Opportunity:

Development of new vaccines

As researchers work on vaccines for challenging diseases like HIV, malaria, and cancer, there is a growing need for potent adjuvants to enhance the efficacy of these vaccines. Novel adjuvants can help stimulate stronger and more targeted immune responses, reduce the amount of antigen required, and enable the use of new vaccine delivery methods. Ongoing research into adjuvants such as saponins, TLR agonists, nanoparticles, and mucosal adjuvants holds promise for the development of more effective and innovative vaccines. The increasing demand for new and improved vaccines is expected to drive the growth of the vaccine adjuvant market in the coming years.

Threat:

Stringent regulatory requirements

Stringent regulatory requirements pose a significant threat to the market due to the lengthy and costly approval processes for new adjuvants. Meeting stringent safety and efficacy standards set by regulatory authorities such as the FDA and EMA requires extensive preclinical and clinical data, prolonging product development timelines. Additionally, any regulatory hurdles or delays in approvals can hinder market entry and limit innovation. Adhering to complex regulatory frameworks adds financial burden and uncertainty for companies, impacting their competitiveness and market growth.

Covid-19 Impact:

The COVID-19 pandemic had a positive impact on the vaccine adjuvants market. The urgent need for effective vaccines drove advancements in adjuvant technologies as researchers explored various formulations to enhance immune responses against the virus. This led to increased demand for adjuvants during the pandemic, with the trend expected to persist in the coming years. The crisis accelerated innovations and discoveries in adjuvants that have broader implications for future vaccine development.

The infectious diseases segment is expected to be the largest during the forecast period

The infectious diseases segment is expected to be the largest in the vaccine adjuvants market during the forecast period due to the rising incidence of infectious diseases globally and the urgent need for effective vaccines. Increasing government initiatives and funding for immunization programs, coupled with advancements in adjuvant technology enhancing vaccine efficacy, are driving this growth. Furthermore, heightened awareness of infectious disease prevention and the ongoing development of vaccines targeting emerging pathogens contribute to the dominance of this segment.

The intramuscular segment is expected to have the highest CAGR during the forecast period

The intramuscular segment is expected to have the highest CAGR in the vaccine adjuvants market during the forecast period. This is because intramuscular injection is the most common method of vaccine administration, as it allows for efficient delivery of the vaccine to the muscle tissue, which has a rich blood supply and contains immune cells that can quickly respond to the vaccine. Intramuscular administration also reduces the risk of local reactions compared to subcutaneous or intradermal routes. Furthermore, many vaccines containing adjuvants are strongly preferred to be administered intramuscularly to optimize immunogenicity and minimize adverse reactions.

Region with largest share:

The Asia Pacific is projected to hold the highest market share in the vaccine adjuvant market due to its large population, increasing prevalence of infectious diseases, and rising awareness about vaccination benefits. Additionally, government initiatives and investments in healthcare infrastructure, coupled with the presence of key market players and an expanding biopharmaceutical industry, contribute to market growth. The region's focus on innovative research and development, along with favorable regulatory environments, further drives the demand for vaccine adjuvants in Asia Pacific region.

Region with highest CAGR:

North America is expected to exhibit the highest CAGR in the vaccine adjuvants market during the forecast period due to advanced healthcare infrastructure, robust R&D activities, and significant investments in vaccine development. The region benefits from strong government support, favorable regulatory frameworks, and a high prevalence of infectious diseases, driving the demand for effective vaccines. Additionally, the presence of leading biopharmaceutical companies and increasing awareness about vaccination's importance contribute to the rapid market growth in North America.

Key players in the market

Some of the key players in Vaccine Adjuvants Market include GlaxoSmithKline plc (GSK), CSL Limited, Novavax, Inc., SPI Pharma, Inc., Seppic (Air Liquide), Invivogen, Croda International Plc, Dynavax Technologies Corporation, Adjuvance Technologies Inc., Agenus Inc., OZ Biosciences, Avanti Polar Lipids, Inc., MVP Laboratories, Inc., Vaxine Pty Ltd, GlycoMira Therapeutics Inc., Pfizer Inc., Sanofi Merck & Co., Inc., Zoetis Inc. and Moderna, Inc.

Key Developments:

In May 2024, Novavax and Sanofi announced a co-exclusive licensing agreement to co-commercialize Novavax's COVID-19 vaccine and develop novel flu-COVID-19 combination vaccines. The deal allows Sanofi to use Novavax's COVID-19 shot and flagship vaccine technology, Matrix-M adjuvant, to develop new vaccine products.

In October 2023, SPI Pharma, Inc. signed a distribution partnership with Q-Vant Biosciences, Inc. The partnership involves the development of Q-Vant's Q-SAP saponin adjuvant technology. The partnership would provide saponin adjuvants to vaccine developers and manufacturers globally.

In July 2023, CSL Seqirus, a business of CSL announced it has begun to ship its portfolio of innovative cell-based, adjuvanted and egg-based influenza vaccines across the U.S. in preparation for the 2023/24 influenza season. The company is positioned to supply over 55 million doses of influenza vaccines to healthcare providers across the U.S.

Adjuvants Types Covered:

  • Alum (Aluminum Hydroxide)
  • Liposomes
  • Viral-Derived Particles (VDPs)
  • Emulsions
  • Carbohydrate Adjuvants
  • Tensoactive Adjuvants
  • Organic Adjuvants
  • Mineral Salt-Based Adjuvants
  • Other Adjuvants Types

Disease Types Covered:

  • Infectious Diseases
  • Cancer
  • Other Disease Types

Vaccine Types Covered:

  • Viral Vaccines
  • Bacterial Vaccines
  • Parasitic Vaccines
  • Other Vaccine Types

Route of Administration Covered:

  • Intramuscular
  • Subcutaneous
  • Intranasal
  • Oral
  • Intradermal

Applications Covered:

  • Research Application
  • Commercial Application

End Users Covered:

  • Human Vaccine Adjuvants
  • Veterinary Vaccine Adjuvants

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Application Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Vaccine Adjuvants Market, By Adjuvant Type

  • 5.1 Introduction
  • 5.2 Alum (Aluminum Hydroxide)
  • 5.3 Liposomes
  • 5.4 Viral-Derived Particles (VDPs)
  • 5.5 Emulsions
  • 5.6 Carbohydrate Adjuvants
  • 5.7 Tensoactive Adjuvants
  • 5.8 Organic Adjuvants
  • 5.9 Mineral Salt-Based Adjuvants
  • 5.10 Other Adjuvants Types

6 Global Vaccine Adjuvants Market, By Disease Type

  • 6.1 Introduction
  • 6.2 Infectious Diseases
  • 6.3 Cancer
  • 6.4 Other Disease Types

7 Global Vaccine Adjuvants Market, By Vaccine Type

  • 7.1 Introduction
  • 7.2 Viral Vaccines
  • 7.3 Bacterial Vaccines
  • 7.4 Parasitic Vaccines
  • 7.5 Other Vaccine Types

8 Global Vaccine Adjuvants Market, By Route of Administration

  • 8.1 Introduction
  • 8.2 Intramuscular
  • 8.3 Subcutaneous
  • 8.4 Intranasal
  • 8.5 Oral
  • 8.6 Intradermal

9 Global Vaccine Adjuvants Market, By Application

  • 9.1 Introduction
  • 9.2 Research Application
  • 9.3 Commercial Application

10 Global Vaccine Adjuvants Market, By End User

  • 10.1 Introduction
  • 10.2 Human Vaccine Adjuvants
  • 10.3 Veterinary Vaccine Adjuvants

11 Global Vaccine Adjuvants Market, By Geography

  • 11.1 Introduction
  • 11.2 North America
    • 11.2.1 US
    • 11.2.2 Canada
    • 11.2.3 Mexico
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 UK
    • 11.3.3 Italy
    • 11.3.4 France
    • 11.3.5 Spain
    • 11.3.6 Rest of Europe
  • 11.4 Asia Pacific
    • 11.4.1 Japan
    • 11.4.2 China
    • 11.4.3 India
    • 11.4.4 Australia
    • 11.4.5 New Zealand
    • 11.4.6 South Korea
    • 11.4.7 Rest of Asia Pacific
  • 11.5 South America
    • 11.5.1 Argentina
    • 11.5.2 Brazil
    • 11.5.3 Chile
    • 11.5.4 Rest of South America
  • 11.6 Middle East & Africa
    • 11.6.1 Saudi Arabia
    • 11.6.2 UAE
    • 11.6.3 Qatar
    • 11.6.4 South Africa
    • 11.6.5 Rest of Middle East & Africa

12 Key Developments

  • 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 12.2 Acquisitions & Mergers
  • 12.3 New Product Launch
  • 12.4 Expansions
  • 12.5 Other Key Strategies

13 Company Profiling

  • 13.1 GlaxoSmithKline plc (GSK)
  • 13.2 CSL Limited
  • 13.3 Novavax, Inc.
  • 13.4 SPI Pharma, Inc.
  • 13.5 Seppic (Air Liquide)
  • 13.6 Invivogen
  • 13.7 Croda International Plc
  • 13.8 Dynavax Technologies Corporation
  • 13.9 Adjuvance Technologies Inc.
  • 13.10 Agenus Inc.
  • 13.11 OZ Biosciences
  • 13.12 Avanti Polar Lipids, Inc.
  • 13.13 MVP Laboratories, Inc.
  • 13.14 Vaxine Pty Ltd
  • 13.15 GlycoMira Therapeutics Inc.
  • 13.16 Pfizer Inc.
  • 13.17 Sanofi
  • 13.18 Merck & Co., Inc.
  • 13.19 Zoetis Inc.
  • 13.20 Moderna, Inc.

List of Tables

  • Table 1 Global Vaccine Adjuvants Market Outlook, By Region (2022-2030) ($MN)
  • Table 2 Global Vaccine Adjuvants Market Outlook, By Adjuvant Type (2022-2030) ($MN)
  • Table 3 Global Vaccine Adjuvants Market Outlook, By Alum (Aluminum Hydroxide) (2022-2030) ($MN)
  • Table 4 Global Vaccine Adjuvants Market Outlook, By Liposomes (2022-2030) ($MN)
  • Table 5 Global Vaccine Adjuvants Market Outlook, By Viral-Derived Particles (VDPs) (2022-2030) ($MN)
  • Table 6 Global Vaccine Adjuvants Market Outlook, By Emulsions (2022-2030) ($MN)
  • Table 7 Global Vaccine Adjuvants Market Outlook, By Carbohydrate Adjuvants (2022-2030) ($MN)
  • Table 8 Global Vaccine Adjuvants Market Outlook, By Tensoactive Adjuvants (2022-2030) ($MN)
  • Table 9 Global Vaccine Adjuvants Market Outlook, By Organic Adjuvants (2022-2030) ($MN)
  • Table 10 Global Vaccine Adjuvants Market Outlook, By Mineral Salt-Based Adjuvants (2022-2030) ($MN)
  • Table 11 Global Vaccine Adjuvants Market Outlook, By Other Adjuvants Types (2022-2030) ($MN)
  • Table 12 Global Vaccine Adjuvants Market Outlook, By Disease Type (2022-2030) ($MN)
  • Table 13 Global Vaccine Adjuvants Market Outlook, By Infectious Diseases (2022-2030) ($MN)
  • Table 14 Global Vaccine Adjuvants Market Outlook, By Cancer (2022-2030) ($MN)
  • Table 15 Global Vaccine Adjuvants Market Outlook, By Other Disease Types (2022-2030) ($MN)
  • Table 16 Global Vaccine Adjuvants Market Outlook, By Vaccine Type (2022-2030) ($MN)
  • Table 17 Global Vaccine Adjuvants Market Outlook, By Viral Vaccines (2022-2030) ($MN)
  • Table 18 Global Vaccine Adjuvants Market Outlook, By Bacterial Vaccines (2022-2030) ($MN)
  • Table 19 Global Vaccine Adjuvants Market Outlook, By Parasitic Vaccines (2022-2030) ($MN)
  • Table 20 Global Vaccine Adjuvants Market Outlook, By Other Vaccine Types (2022-2030) ($MN)
  • Table 21 Global Vaccine Adjuvants Market Outlook, By Route of Administration (2022-2030) ($MN)
  • Table 22 Global Vaccine Adjuvants Market Outlook, By Intramuscular (2022-2030) ($MN)
  • Table 23 Global Vaccine Adjuvants Market Outlook, By Subcutaneous (2022-2030) ($MN)
  • Table 24 Global Vaccine Adjuvants Market Outlook, By Intranasal (2022-2030) ($MN)
  • Table 25 Global Vaccine Adjuvants Market Outlook, By Oral (2022-2030) ($MN)
  • Table 26 Global Vaccine Adjuvants Market Outlook, By Intradermal (2022-2030) ($MN)
  • Table 27 Global Vaccine Adjuvants Market Outlook, By Application (2022-2030) ($MN)
  • Table 28 Global Vaccine Adjuvants Market Outlook, By Research Application (2022-2030) ($MN)
  • Table 29 Global Vaccine Adjuvants Market Outlook, By Commercial Application (2022-2030) ($MN)
  • Table 30 Global Vaccine Adjuvants Market Outlook, By End User (2022-2030) ($MN)
  • Table 31 Global Vaccine Adjuvants Market Outlook, By Human Vaccine Adjuvants (2022-2030) ($MN)
  • Table 32 Global Vaccine Adjuvants Market Outlook, By Veterinary Vaccine Adjuvants (2022-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.